Figure 5
Effective dosing period of KAOD on hepatoprotection. Serum and livers were harvested from ICR mice fed KAOD-10% ad libitum from day 9 until the end of the experiment, from day 9 until CCl4 injection or from CCl4 injection until the end of the experiment. (A) The activities of ALT, AST, and LDH in the serum of KAOD-10%-administered mice (a) for 2 days, (b) for 24 h from day 9 until CCl4 injection or (c) for 24 h from CCl4 injection until the end of the experiment were measured using commercially available kits. Data are presented as mean ± standard deviation, n =6. Significant difference from AIN-93G: *p <0.05; **p <0.01; n.s.: not significant. (B) HE stained liver sections from mice administered (a-1) AIN-93G with CCl4 (control for 2 days), (a-2) KAOD-10% (2 days) with CCl4, (b-1) AIN-93G with CCl4 (control for pre-ingestion group), (b-2) KAOD-10% (pre-ingestion group) with CCl4, (c-1) AIN-93G with CCl4 (control for post-ingestion group), (c-2) KAOD-10% (post-ingestion group) with CCl4. Scale bar =100 μm.